Page 42 - யேல் பல்கலைக்கழகம் பள்ளி ஆஃப் மருந்து News Today : Breaking News, Live Updates & Top Stories | Vimarsana

email article Transcatheter aortic valve replacement (TAVR) with CoreValve and Evolut devices maintained good results in the Evolut Low Risk Trial through 2 years, with investigators now boasting complete follow-up and no more need to rely on Bayesian analysis. In 2019, a prespecified interim analysis of the trial found that the primary endpoint all-cause mortality or disabling stroke at 24 months occurred in 5.3% of TAVR recipients compared with 6.7% of the surgical group under Bayesian methods, demonstrating that TAVR was noninferior for efficacy. Now, with complete follow-up, 2-year event rates were 4.3% and 6.3%, respectively (log-rank P=0.084), such that TAVR looks, at least numerically, even better than before, said John Forrest, MD, of Yale University School of Medicine in New Haven, Connecticut, during a presentation at this year s virtual European Association of Percutaneous Cardiovascular Interventions (EuroPCR) meeting.

New havenUnited statesYale universityNicole louJohn forrestEuropean association of percutaneous cardiovascular interventionsPeuropean association of percutaneous cardiovascular interventions euroYale university school of medicineEvolut low risk trialYale university schoolEuropean associationPercutaneous cardiovascular interventionsMedpage todayPercutaneous cardiovascularபுதியது புகலிடம்ஒன்றுபட்டது மாநிலங்களில்